Ranbaxy, Teva Agree to Settle New York Antitrust Claims

Ranbaxy Pharmaceuticals Inc. and Teva Pharmaceuticals Inc.’s U.S. unit agreed to settle New York state claims that they colluded on generic-drug sales, including copies of the world’s best-selling medicine Lipitor.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.